Vasovist is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system through magnetic resonance angiography imaging (MRA). Vasovist has been approved for marketing
The council will be headed by Humaid Mohammad Al Qutami, Health Minister who will select two representatives from each of the institutions: the Ministry of Health, the Abu
The clinical study was designed to evaluate the safety and prevented pregnancy rate of SOH-075 (NorLevo) in Japanese adult female subjects who require emergency contraception. No serious adverse
Sanghyon Chemical will provide for the registration of Davanat with the Korean FDA and marketing and sales support for the licensing and distribution of Davanat to treat cancer
ZB-202 is a randomized, double-blind, placebo-controlled trial involving approximately 720 generally healthy, nondiabetic obese patients at 20 sites nationwide. The primary endpoint for this trial is percent change
GlobeImmune will utilize its proprietary Tarmogen technology to develop multiple immunotherapy products expressing various cancer antigens provided by the National Institutes of Health (NIH) and the NIH will
Under the terms of the put agreement, Commonwealth Biotechnologies (CBI) sold 463,426 shares of common stock to Venturepharm Laboratories (VPL) at a price of $2.15 per share, a
Under the terms of the ten year agreement, Akorn will be responsible for the manufacturing and supply of several injectable drug products. Akorn anticipates annual contract revenue from
The Cerecyte product line includes the MicruSphere, Presidio, HeliPaq and UltiPaq Cerecyte embolic coils, for the endovascular treatment of cerebral aneurysms. Sales of the company’s Cerecyte microcoils will
Approved by the FDA for postoperative nausea and vomiting, Aloxi injection 0.075mg is administered as a single IV dose immediately before induction of anesthesia to prevent PONV for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.